Home
>
US Stocks
>
Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc
ALDX

Aldeyra Therapeutics Inc (ALDX)

$8.048.84%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
7.95
Today Low/High
7.87 / 8.04
52 Week Low/High
$5.53 / $15.95
Market Cap
$506.31M

Company Details

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.
Organisation
Aldeyra Therapeutics Inc
Employees
11
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Aldeyra Therapeutics Inc (ALDX) share price today?

Can Indians buy Aldeyra Therapeutics Inc (ALDX) shares?

How can I buy Aldeyra Therapeutics Inc (ALDX) shares from India?

Can Fractional shares of Aldeyra Therapeutics Inc (ALDX) be purchased?

What are the documents required to start investing in Aldeyra Therapeutics Inc (ALDX) stocks?

We are a SEBI registered investement advisor